Recently, mammalian target of rapamycin (mTOR) inhibitor revealed an anti-tumor effect in post-transplant recipients with switching regimen, however, there was also reversed opinion about this protective effect [30, 31]. The gene discussed is MTOR; the disease is neoplasm.